DOI: https://doi.org/10.22263/2312-4156.2024.1.25
H.A. Zhernasechanka1,2, M.A. Novikova1, Y.I. Isaikina1
Modern ideas about the role of various T-lymphocytes subpopulations in the development of graft-versus-host disease
1Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Republic of Belarus
2Belarusian State Medical University, Minsk, Republic of Belarus
Vestnik VGMU. 2024;23(1):25-33.
Abstract.
Graft-versus-host disease (GVHD) is a serious complication after allogeneic hematopoietic stem cell transplantation, which is the main cause of death in more than 10% of patients. This review summarises the information about the immunological mechanisms of the development of acute and chronic GVHD. The analysis has shown that we have a large theoretical knowledge base about the developmental process and the role of various subpopulations of T-cells in GVHD. Growing understanding of the mechanisms of GVHD will expand the possibilities of using new therapeutic approaches for the prevention and treatment of this complication of allogeneic hematopoietic stem cell transplantation.
Keywords: graft -versus-host disease, T-lymphocytes, T-regulators.
References
1. Justiz Vaillant AA, Modi P, Mohammadi O. Graft-Versus-Host Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://pubmed.ncbi.nlm.nih.gov/30855823/ [Accessed 27th February 2024].
2. Aladağ E, Kelkitli E, Göker H. Acute Graft-Versus-Host Disease: A Brief Review. Turk J Haematol. 2020 Feb;37(1):1-4. doi: http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0157
3. Fang Y, Zhu Y, Kramer A, Chen Y, Li YR, Yang L. Graft-versus-Host Disease Modulation by Innate T Cells. Int J Mol Sci. 2023 Feb;24(4):4084. doi: http://dx.doi.org/10.3390/ijms24044084
4. Hamilton BK. Updates in chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2021 Dec;2021(1):648-54. doi: http://dx.doi.org/10.1182/hematology.2021000301
5. Zeiser R. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol. 2019 Dec;187(5):563-72. doi: http://dx.doi.org/10.1111/bjh.16190
6. Hill GR, Koyama M. Cytokines and costimulation in acute graft-versus-host disease. Blood. 2020 Jul;136(4):418-28. doi: http://dx.doi.org/10.1182/blood.2019000952
7. Jiang H, Fu D, Bidgoli A, Paczesny S. T-CellSubsets in Graft Versus Host Diseaseand Graft Versus Tumor. Front Immunol. 2021 Oct:12:761448. doi: http://dx.doi.org/10.3389/fimmu.2021.761448
8. Hill GR, Betts BC, Tkachev V, Kean LS, Blazar BR. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol. 2021 Apr:39:19-49. doi: http://dx.doi.org/10.1146/annurev-immunol-102119-073227
9. Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage. Nat Med. 2014 Jun;20(6):648-54. doi: http://dx.doi.org/10.1038/nm.3517
10. Hülsdünker J, Ottmüller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, et al. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood. 2018 Apr;131(16):1858-69. doi: http://dx.doi.org/10.1182/blood-2017-10-812891
11. Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017 Dec;377(26):2565-79. doi: http://dx.doi.org/10.1056/NEJMra1703472
12. Zhang M, Zhang S. T Cells in Fibrosis and Fibrotic Diseases. Front Immunol. 2020 Jun:11:1142. doi: http://dx.doi.org/10.3389/fimmu.2020.01142
13. Blazar BR, Taylor PA, Vallera DA. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation. 1997 Aug;64(4):571-6. doi: http://dx.doi.org/10.1097/00007890-199708270-00004
14. Klicznik MM, Morawski PA, Höllbacher B, Varkhande SR, Motley SJ, Kuri-Cervantes L, et al. Human CD4+CD103+ cutaneous resident memory T cells are found in the circulation of healthy subjects. Sci Immunol. 2019 Jul;4(37):eaav8995. doi: http://dx.doi.org/10.1126/sciimmunol.aav8995
15. Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al. Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. Cell Rep. 2017 Sep;20(12):2921-34. doi: http://dx.doi.org/10.1016/j.celrep.2017.08.078
16. Yenyuwadee S, Sanchez-Trincado Lopez JL, Shah R, Rosato PC, Boussiotis VA. The evolving role of tissue-resident memory T cells in infections and cancer. Sci Adv. 2022 Aug;8(33):eabo5871. doi: http://dx.doi.org/10.1126/sciadv.abo5871
17. Strobl J, Gail LM, Kleissl L, Pandey RV, Smejkal V, Huber J, et al. Human resident memory T cells exit the skin and mediate systemic Th2-driven inflammation. J Exp Med. 2021 Nov;218(11):e20210417. doi: http://dx.doi.org/10.1084/jem.20210417
18. Brüggen MC, Klein I, Greinix H, Bauer W, Kuzmina Z, Rabitsch W, Kalhs P, et al. Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. Blood. 2014 Jan;123(2):290-9. doi: http://dx.doi.org/10.1182/blood-2013-07-514372
19. Chang HCh, Sehra S, Goswami R, Yao W, Yu Q, Stritesky GL, Jabeen R, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol. 2010 Jun;11(6):527-34. doi: http://dx.doi.org/10.1038/ni.1867
20. Lu Y, Hong B, Li H, Zheng Y, Zhang M, Wang S, et al. Tumor-Specific IL-9-Producing CD8+ Tc9 Cells are Superior Effector Than Type-I Cytotoxic Tc1 Cells for Adoptive Immunotherapy of Cancers. Proc Natl Acad Sci U S A. 2014 Feb;111(6):2265-70. doi: http://dx.doi.org/10.1073/pnas.1317431111
21. Delia M, Carluccio P, Mestice A, Chiusolo P, Metafuni E, Bellesi S, et al. The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. Transplant Cell Ther. 2021 Nov;27(11):918.e1-918.e9. doi: http://dx.doi.org/10.1016/j.jtct.2021.08.008
22. Zheleznikova GF. Regulatory T lymphocytes in the immune response to infection. Zhurn Infektologii. 2011;3(1):6-13. (In Russ.)
23. Guo WW, Su XH, Wang MY, Han MZ, Feng XM, Jiang EL. Regulatory T Cells in GVHD Therapy. Front Immunol. 2021 Jun:12:697854. doi: http://dx.doi.org/10.3389/fimmu.2021.697854
24. Gregori S, Roncarolo MG. Engineered T regulatory type 1 cells for clinical application. Front Immunol. 2018 Feb:9:233. doi: http://dx.doi.org/10.3389/fimmu.2018.00233
25. Blazar BR, MacDonald KPA, Hill GR. Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. Blood. 2018 Jun;131(24):2651-60. doi: http://dx.doi.org/10.1182/blood-2017-11-785865
26. Soukou-Wargalla S, Kilian C, Velasquez LN, Machicote A, Letz P, Tran HB, et al. Tr1 Cells Emerge and Suppress Effector Th17 Cells in Glomerulonephritis. J Immunol. 2023 Dec;211(11):1669-79. doi: http://dx.doi.org/10.4049/jimmunol.2300305
27. Wang W, Hong T, Wang X, Wang R, Du Y, Gao Q, et al. Newly Found Peacekeeper: Potential of CD8+ Tregs for Graft-Versus-Host Disease. Front Immunol. 2021 Nov:12:764786. doi: http://dx.doi.org/10.3389/fimmu.2021.764786
28. Heinrichs J, Li J, Nguyen H, Wu Y, Bastian D, Daethanasanmak A, et al. CD8+Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4+Tregs in mice. Oncoimmunology. 2016 Mar;5(6):e1146842. doi: http://dx.doi.org/10.1080/2162402X.2016.1146842
Information about authors:
H.A. Zhernasechanka – Candidate of Biological Sciences, leading research officer of the Laboratory of Cellular Biotechnologies and Cytotherapy, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology; associate professor of the Chair of Pediatric Endocrinology, Clinical Genetics and Immunology, Belarusian State Medical University,
e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Hanna A. Zhernasechanka;
M.A. Novikova – research officer of the Laboratory of Cellular Biotechnologies and Cytotherapy, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology;
Y.I. Isaikina – Candidate of Biological Sciences, head of the Laboratory of Cellular Biotechnologies and Cytotherapy, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology.
